Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters.

IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Song Gao, Yuexiang Liang, Jun Yu, Shaofei Chang, Hongwei Wang, Tiansuo Zhao, Xiuchao Wang, Quan Man, Zhifei Li, Yiping Zou, Kuirong Jiang, Chuntao Gao, Jihui Hao
{"title":"Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters.","authors":"Song Gao, Yuexiang Liang, Jun Yu, Shaofei Chang, Hongwei Wang, Tiansuo Zhao, Xiuchao Wang, Quan Man, Zhifei Li, Yiping Zou, Kuirong Jiang, Chuntao Gao, Jihui Hao","doi":"10.20892/j.issn.2095-3941.2025.0213","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Current clinical staging of pancreatic ductal adenocarcinoma (PDAC) relies predominantly on anatomical resectability, thus limiting its prognostic utility. We developed and validated a pretreatment prognostic grading system incorporating multidimensional parameters.</p><p><strong>Methods: </strong>Patients with histologically confirmed PDAC undergoing curative-intent pancreatectomy were retrospectively enrolled. Independent prognostic determinants of overall survival (OS) and disease-free survival (DFS), identified through multivariable Cox proportional hazards regression, provided the basis for deriving the Tianjin Prognostic Score and its corresponding risk stratification scheme.</p><p><strong>Results: </strong>Resectability status, lymph node metastasis indicated by imaging, pretreatment serum CA19-9 levels, and the prognostic nutritional score (PNS) independently predicted both OS and DFS. These parameters were integrated into the Tianjin Prognostic Score for PDAC prognosis stratification. The Tianjin-Grade system, subsequently established according to this score, segregated patients into 4 discrete prognostic cohorts with significantly divergent survival outcomes. This system exhibited significantly greater discriminatory ability for prognosis than conventional serum CA19-9 and resectability criteria. Notably, patients classified as having high risk or extremely high risk derived substantial survival benefits from neoadjuvant chemotherapy (NAC), whereas those with low or intermediate risk demonstrated comparable survival outcomes regardless of NAC administration.</p><p><strong>Conclusions: </strong>The Tianjin-Grade system provides accurate pretreatment prognosis prediction in patients with PDAC through integration of anatomical and biological parameters, thus serving as a reliable tool for prognostic assessment. This system facilitates the development of personalized preoperative therapeutic strategies.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2025.0213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Current clinical staging of pancreatic ductal adenocarcinoma (PDAC) relies predominantly on anatomical resectability, thus limiting its prognostic utility. We developed and validated a pretreatment prognostic grading system incorporating multidimensional parameters.

Methods: Patients with histologically confirmed PDAC undergoing curative-intent pancreatectomy were retrospectively enrolled. Independent prognostic determinants of overall survival (OS) and disease-free survival (DFS), identified through multivariable Cox proportional hazards regression, provided the basis for deriving the Tianjin Prognostic Score and its corresponding risk stratification scheme.

Results: Resectability status, lymph node metastasis indicated by imaging, pretreatment serum CA19-9 levels, and the prognostic nutritional score (PNS) independently predicted both OS and DFS. These parameters were integrated into the Tianjin Prognostic Score for PDAC prognosis stratification. The Tianjin-Grade system, subsequently established according to this score, segregated patients into 4 discrete prognostic cohorts with significantly divergent survival outcomes. This system exhibited significantly greater discriminatory ability for prognosis than conventional serum CA19-9 and resectability criteria. Notably, patients classified as having high risk or extremely high risk derived substantial survival benefits from neoadjuvant chemotherapy (NAC), whereas those with low or intermediate risk demonstrated comparable survival outcomes regardless of NAC administration.

Conclusions: The Tianjin-Grade system provides accurate pretreatment prognosis prediction in patients with PDAC through integration of anatomical and biological parameters, thus serving as a reliable tool for prognostic assessment. This system facilitates the development of personalized preoperative therapeutic strategies.

胰腺癌综合预处理分层系统:结合解剖可切除性和肿瘤生物学参数。
目的:目前胰腺导管腺癌(PDAC)的临床分期主要依赖于解剖上的可切除性,从而限制了其预后的应用。我们开发并验证了一个包含多维参数的预处理预后分级系统。方法:回顾性纳入组织学证实的PDAC患者,并行胰切除术。通过多变量Cox比例风险回归确定总生存期(OS)和无病生存期(DFS)的独立预后决定因素,为导出天津预后评分及其相应的风险分层方案提供了基础。结果:可切除状态、影像学显示的淋巴结转移、预处理血清CA19-9水平和预后营养评分(PNS)独立预测OS和DFS。这些参数被纳入天津预后评分,用于PDAC预后分层。随后根据该评分建立的天津分级系统将患者分为4个独立的预后队列,这些队列的生存结果存在显著差异。与传统的血清CA19-9和可切除性标准相比,该系统对预后的鉴别能力显著提高。值得注意的是,被归类为高风险或极高风险的患者从新辅助化疗(NAC)中获得了大量的生存益处,而那些低风险或中等风险的患者无论是否给予NAC,其生存结果都相当。结论:天津分级系统通过结合解剖和生物学参数对PDAC患者进行准确的预处理预后预测,可作为一种可靠的预后评估工具。该系统促进了个性化术前治疗策略的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Biology & Medicine
Cancer Biology & Medicine Medicine-Oncology
CiteScore
9.80
自引率
3.60%
发文量
1143
审稿时长
12 weeks
期刊介绍: Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信